Quick Takeaways
- Bellevue Group AG filed SCHEDULE 13G/A for Agios Pharmaceuticals, Inc. Common Stock (AGIO).
- Disclosed ownership: 0%.
- Date of event: 19 Nov 2025.
Bellevue Group AG - 19 Nov 2025 SCHEDULE 13G/A Report for Agios Pharmaceuticals, Inc. Common Stock (AGIO)
- Filing Manager
- Bellevue Group AG
- Reporting Manager
- Bellevue Group AG
- Symbol
- AGIO
- Disclosed Ownership
- 0 shares
- Ownership
- 0%
- Form type
- SCHEDULE 13G/A
- Filing time
- 05 Dec 2025, 17:42:25 UTC
- Date of event
- 19 Nov 2025
- Previous filing
- 07 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Bellevue Group AG disclosed 0% ownership in Agios Pharmaceuticals, Inc. Common Stock (AGIO) on 19 Nov 2025."
What Changed
- Previous schedule filing date: 07 Jul 2025.
- Current filing was accepted on 05 Dec 2025, 17:42.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Bellevue Group AG | 0% | 0 | 0 | 0 | /s/ Stefano Montalbano | Stefano Montalbano/ Chief Financial Officer | |
| Bellevue Asset Management AG | 0% | 0 | 0 | 0 | /s/ Christoph Eisenring | Christoph Eisenring/ Head Legal & Compliance |